Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Phase 2

Completed

• Conditions: Breast Cancer
• Interventions: Drug: Letrozole

• Registration Number: NCT00535418
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study will assess optimal duration of pre-operative treatment with letrozole and to correlate clinical efficacy with appropriate surrogate markers.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-06
• Primary Completion: 2002-07
• Study First Submitted: 2007-09-24
• Study First Submitted QC: 2007-09-25
• Study First Posted: 2007-09-26
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-31
• Last Update Posted: 2017-09-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 35

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Letrozole	Letrozole	-